MaxCyte MXCT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$39.12M+12.3% | -$44.63M+2.2% | -$45.63M-1.9% | -$44.77M-7.1% | -$41.79M-1.8% | ||
| $4.29M-1.1% | $4.34M+0.3% | $4.33M+0.1% | $4.32M+0.4% | $4.3M-0.3% | ||
| $7.32M-20.6% | $9.21M-20.9% | $11.64M-10.8% | $13.06M-0.4% | $13.11M+0.2% | ||
| —— | $3.55M— | —— | —— | —— | ||
| —— | -$287K+46.0% | -$531K+13.4% | -$613K— | —— | ||
| -$1.24M-8.4% | -$1.15M-131% | $3.65M+246% | $1.06M+224% | -$852K+36.8% | ||
| —— | —— | —— | -$1.28M+25.6% | -$1.72M-26.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $2.03M+35.5% | $1.5M+23.7% | ||
| —— | —— | -$50K+19.4% | -$62K-589% | -$9K0.0% | ||
| —— | —— | —— | —— | —— | ||
| $842K+5.0% | $802K+13.1% | $709K+14.4% | $620K+14.8% | $540K+13.7% | ||
| -$1.34M-15.4% | -$1.16M+5.5% | -$1.22M-12.6% | -$1.09M-23.0% | -$884K-24.7% | ||
| -$28.17M+18.1% | -$34.41M+13.0% | -$39.54M-8.4% | -$36.48M-16.0% | -$31.46M-13.9% | ||
| $1.19M-32.9% | $1.77M+5.0% | $1.68M-5.9% | $1.79M+19.3% | $1.5M-9.1% | ||
| —— | —— | —— | —— | —— | ||
| $116.76M-7.5% | $126.29M-3.3% | $130.55M-3.3% | $135.03M-1.8% | $137.46M-8.9% | ||
| $137.16M-11.9% | $155.76M+4.8% | $148.6M-2.0% | $151.6M-11.6% | $171.59M+7.6% | ||
| —— | —— | —— | —— | —— | ||
| $19.06M-26.5% | $25.94M— | —— | —— | —— | ||
| $54K-87.5% | $432K-32.0% | $635K-25.2% | $849K-33.5% | $1.28M-20.0% | ||
| $278K-57.6% | $656K-31.9% | $963K-18.2% | $1.18M-32.2% | $1.74M-15.6% | ||
| —— | —— | -$23.99M-7.6% | -$22.29M— | —— | ||
| $2.2M-16.9% | $2.65M-22.4% | $3.41M-19.1% | $4.21M-18.1% | $5.14M-17.6% | ||
| —— | —— | —— | —— | —— | ||
| -$1.34M-15.4% | -$1.16M+5.5% | -$1.22M-12.6% | -$1.09M-23.0% | -$884K-24.7% | ||
| $527K-0.8% | $531K+142% | -$1.26M-593% | $256K-22.7% | $331K+213% | ||
| $808K+19.5% | $676K-53.8% | $1.46M-18.7% | $1.8M— | —— | ||
| —— | —— | —— | —— | —— | ||
| $842K+5.0% | $802K+13.1% | $709K+14.4% | $620K+14.8% | $540K+13.7% | ||
| —— | —— | —— | —— | —— | ||
| $137.16M-11.9% | $155.76M+4.8% | $148.6M-2.0% | $151.6M-11.6% | $171.59M+7.6% | ||
| —— | —— | —— | —— | —— | ||
| -$1.34M-15.4% | -$1.16M+5.5% | -$1.22M-12.6% | -$1.09M-23.0% | -$884K-24.7% | ||
| —— | —— | —— | —— | —— | ||
| -$29.36M+18.9% | -$36.18M+12.2% | -$41.23M-7.7% | -$38.27M-16.1% | -$32.96M-12.6% | ||
| -$29.36M+18.9% | -$36.18M+12.2% | -$41.23M-7.7% | -$38.27M-16.1% | -$32.96M-12.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does MaxCyte generate?
- MaxCyte (MXCT) generated -$28.2M in operating cash flow over the trailing twelve months.
- What is MaxCyte's free cash flow?
- After $1.2M of capital expenditures, MaxCyte's free cash flow was -$29.4M over the trailing twelve months, up 10.9% year over year.
- Where does MaxCyte's cash flow data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
